Pharmacokinetics and tolerability of atomoxetine in adults of known CYP2D6 phenotype.

被引：0
|
作者：
Witcher, J [1 ]
Long, A [1 ]
Sauer, JM [1 ]
Smith, B [1 ]
Read, H [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2005年 / 77卷 / 02期
关键词：
D O I：
10.1016/j.clpt.2004.11.103
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P27 / P27
页数：1
相关论文
共 50 条
  • [21] Effect of CYP2D6 phenotype and metoprolol pharmacokinetics on adverse effects.
    Beitelshees, AL
    Zineh, I
    Gaedigk, A
    Leeder, JS
    Walker, JR
    Eberst, K
    Timmerbeil, BS
    Lobmeyer, M
    Pauly, DF
    Johnson, JA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P94 - P94
  • [22] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
  • [23] CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders
    Jallaq, Sahar A.
    Verba, Mark
    Strawn, Jeffrey R.
    Martin, Lisa J.
    DelBello, Melissa P.
    Ramsey, Laura B.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2021, 31 (01) : 56 - 62
  • [24] Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers
    Chung, Woo Kyung
    Hwang, Inyoung
    Kim, Byungwook
    Jung, Jihyun
    Yu, Kyung-Sang
    Jang, In-Jin
    Oh, Jaeseong
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (03): : 512 - 523
  • [25] CYP2D6 and chlorpheniramine pharmacokinetics.
    Yasuda, SU
    Zannikos, P
    Young, AE
    Fried, KM
    Wainer, JW
    Woosley, RL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P7 - P7
  • [26] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    Gressier, F.
    Verstuyft, C.
    Hardy, P.
    Becquemont, L.
    Corruble, E.
    JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (01) : 35 - 42
  • [27] CONCORDANCE OF PHENOTYPE AND GENOTYPE FOR CYP2D6
    MCLEOD, HL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (04) : 463 - 463
  • [28] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    F. Gressier
    C. Verstuyft
    P. Hardy
    L. Becquemont
    E. Corruble
    Journal of Neural Transmission, 2015, 122 : 35 - 42
  • [29] Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms
    O. Spigset
    K. Granberg
    S. Hägg
    Å. Norström
    R. Dahlqvist
    European Journal of Clinical Pharmacology, 1997, 52 : 129 - 133
  • [30] Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms
    Spigset, O
    Granberg, K
    Hagg, S
    Norstrom, A
    Dahlqvist, R
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (02) : 129 - 133
12345